APIJECT SYSTEMS, CORP. — Lobbying Disclosure | Poliscope

APIJECT SYSTEMS, CORP.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	5	2
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
AVOQ, LLC	—	22
THE DUBERSTEIN GROUP INC.	—	7

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	26
SENATE	25
Executive Office of the President (EOP)	14
Export-Import Bank of the United States (EXIM Bank)	7
Health & Human Services, Dept of (HHS)	6
White House Office	6
Commerce, Dept of (DOC)	4
Food & Drug Administration (FDA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	23
Health Issues	Health Issues	10
Budget/Appropriations	Budget/Appropriations	10
Manufacturing	Manufacturing	6

Bills Explicitly Cited (3)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 3588117th Congress

Medical Countermeasures Surge Capacity Act of 2022

2022 · second_quarter · Firm: AVOQ, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the availability of vaccine/therapeutic delivery systems Issues related to global health and syringe shortages Issues related to S.3588 (Medical Countermeasures Surge Capacity Act of 2022)

Client expense: — · Firm income: $60,000

Matched citations: S.3588

S. 3588117th Congress

Medical Countermeasures Surge Capacity Act of 2022

2022 · first_quarter · Firm: AVOQ, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the availability of vaccine/therapeutic delivery systems Issues related to global health and syringe shortages Issues related to S.3799 (PREVENT Pandemics Act) Issues related to S.3588 (Medical Countermeasures Surge Capacity Act of 2022)

Client expense: — · Firm income: $60,000

Matched citations: S.3588

S. 3799117th Congress

PREVENT Pandemics Act

2022 · first_quarter · Firm: AVOQ, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the availability of vaccine/therapeutic delivery systems Issues related to global health and syringe shortages Issues related to S.3799 (PREVENT Pandemics Act) Issues related to S.3588 (Medical Countermeasures Surge Capacity Act of 2022)

Client expense: — · Firm income: $60,000

Matched citations: S.3799

Source: Senate LDA